ArticleJournal for immunotherapy of cancer2025
Clonal hematopoiesis is associated with reduced response to atezolizumab in non-small cell lung cancer.
Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab.Molecular oncology · 2025Trial
- Clonal Hematopoiesis in Colorectal Cancer: Mechanisms and Implications.Cancer medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe acquisition of somatic mutations associated with the expansion of certain hematopoietic stem cells is known as clonal hematopoiesis (CH). Despite evidence of CH association with age-related pro-inflammatory diseases, little is known about its role in the response to antitumor immune modulatory therapies such as immune-checkpoint inhibition (ICI). In this report, we characterize the effect of CH on ICI objective response in non-small cell lung cancer (NSCLC).
methodsWe performed baseline blood-derived whole-exome sequencing of 1,281 patients with NSCLC from five anti-programmed death ligand-1 (PD-L1) trials (FIR, POPLAR, IMpower110, IMpower150, and IMpower131). Multivariable logistic regression adjusting for age, sex, and smoking history was used to model the odds of being a non-responder in each trial, and random effects meta-analyses were performed in anti-PD-L1 and comparator arms.
resultsCH carriage, defined as the presence of CH with variant allele fraction≥2%, was associated with adverse objective response across the anti-PD-L1 treatment arms (OR=1.69 (95% CI 1.08 to 2.63); p=0.02). No association was observed in the comparator arms (OR=0.61 (95% CI 0.31 to 1.21); p=0.16). CH carriers had lower absolute leukocyte counts (p
conclusionsIn this report, we provide evidence of the adverse impact of CH on ICI treatment objective response in NSCLC, highlighting CH as a potential predictive biomarker for patient stratification in ICI. Further experimental validation is needed to better understand the mechanism of action behind this reduction in ICI efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.